A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

NCT00147589

Last updated date
Study Location
Pfizer Investigational Site
Little Rock, Arkansas, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-16 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- 6-16 years old male and female

- Systolic blood pressure greater than or equal to the 95th percentile for age, gender, and height, measured on at least 3 separate occasions

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- K/DOQI classification of stages of chronic kidney disease equal to or greater than 3


- Serum or whole blood potassium > 5.5 mEq/L

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

HypertensionAmlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients
NCT01200407
  1. San Fernando City, La Union
  2. Taclobo, Dumaguete City, Negros Oriental
  3. Albay,
  4. Angono,
  5. Baguio City,
  6. Baguio,
  7. Bulacan,
  8. Calamba,
  9. Cavite,
  10. Cebu City,
  11. Cebu,
  12. Dagupan,
  13. Davao City,
  14. Davao,
  15. Eastwood,
  16. Iloilo City,
  17. Iloilo,
  18. Isabela,
  19. Kalibo Aklan,
  20. Laguna,
  21. Laoag,
  22. Lingayen, Pangasinan,
  23. Makati City,
  24. Makati City,
  25. Makati,
  26. Mandaluyong,
  27. Manila,
  28. Manila,
  29. Manila,
  30. Manila,
  31. Manila,
  32. Manila,
  33. Marikina City,
  34. Marikina,
  35. Metro Manila,
  36. Muntinlupa,
  37. Nueva Vizcaya,
  38. Olongapo,
  39. Pampanga,
  40. Paranaque,
  41. Parañaque,
  42. Pasay,
  43. Pasig City,
  44. Pasig Ciy,
  45. Pasig,
  46. Pasig,
  47. Puerto Princesa,
  48. Quezon City,
  49. Quezon CIty,
  50. Rizal,
  51. San Juan,
  52. Tacloban,
  53. Taguig,
  54. Tarlac,
  55. Tugegarao,
  56. Tuguegarao City,
  57. Tuguegarao City,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypertensionA Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents
NCT00389519
  1. Little Rock, Arkansas
  2. Little Rock, Arkansas
  3. Beverly Hills, California
  4. Los Angeles, California
  5. Orange, California
  6. Cocoa Beach, Florida
  7. Lakeland, Florida
  8. Atlanta, Georgia
  9. Augusta, Georgia
  10. Honolulu, Hawaii
  11. Park Ridge, Illinois
  12. Tinley Park, Illinois
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bridgeton, Missouri
  16. Las Vegas, Nevada
  17. Las Vegas, Nevada
  18. Toms River, New Jersey
  19. Syracuse, New York
  20. Williamsville, New York
  21. Cary, North Carolina
  22. Chapel Hill, North Carolina
  23. Durham, North Carolina
  24. Sylva, North Carolina
  25. Cincinnati, Ohio
  26. Columbus, Ohio
  27. Norman, Oklahoma
  28. Tulsa, Oklahoma
  29. Portland, Oregon
  30. Portland, Oregon
  31. Philadelphia, Pennsylvania
  32. Kingsport, Tennessee
  33. Memphis, Tennessee
  34. Beaumont, Texas
  35. Houston, Texas
  36. Salt Lake City, Utah
  37. Charlottesville, Virginia
  38. Midlothian, Virginia
  39. Norfolk, Virginia
  40. Buenos Aires,
  41. Buenos Aires,
  42. Buenos Aires,
  43. Buenos Aires,
  44. San Juan,
  45. Tucomán,
  46. Santiago,
  47. Santiago,
  48. Santiago,
  49. Vina del Mar,
  50. Barranquilla,
  51. Bogotá,
  52. Bogotá,
  53. Bogotá,
  54. Medellin,
  55. Medellin,
  56. Medellín,
  57. Ahmedabad,
  58. Ahmedabad,
  59. Bangalore,
  60. Chennai,
  61. Delhi,
  62. Delhi,
  63. Delhi,
  64. Hyderabaad,
  65. Hyderabaad,
  66. Ludhiana,
  67. Mumbai,
  68. Pune,
  69. Trivandrum,
  70. Gdansk,
  71. Katowice,
  72. Lodz,
  73. Lodz,
  74. Poznan,
  75. Szczecin,
  76. Szczecin,
  77. Torun,
  78. Warszawa,
  79. Wroclaw,
  80. Benoni,
  81. Johannesburg,
  82. Port Elizabeth,
  83. Potchefstroom,
  84. Pretoria,
  85. Pretoria,
  86. Pretoria,
  87. Pretoria,
  88. Sandton,
  89. Istanbul,
  90. Istanbul,
  91. Izmir,
  92. Samsun,
  93. Dnepropetrovsk,
  94. Kharkov,
  95. Kiev,
  96. Kyiv,
  97. Lviv,
  98. Odessa,
  99. Simferopol,
  100. Uzhorod,
  101. Vinnitsa,
ALL GENDERS
6 Years+
years
MULTIPLE SITES
HypertensionA Comparative Study Between Amlodipine 10mg And 5mg With Hypertension For Whom 5mg Is Insufficient
NCT00415623
  1. Kasuya-gun, Fujuoka
  2. Chikushino, Fukuoka
  3. Kitakyushu, Fukuoka
  4. Koga, Fukuoka
  5. Sapporo, Hokkaidou
  6. Sapporo, Hokkaido
  7. Yokohama, Kanagawa
  8. Iruma, Saitama
  9. Koshigaya, Saitama
  10. Adachi-ku, Tokyo
  11. Edogawa-ku, Tokyo
  12. Meguro-ku, Tokyo
  13. Setagaya-ku, Tokyo
  14. Sumida, Tokyo
  15. Fukuoka,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
HypertensionTreatment of Pediatric Hypertension With Altace Trial
NCT00044265
  1. Birmingham, Alabama
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Augusta, Georgia
  6. Honolulu, Hawaii
  7. Park Ridge, Illinois
  8. Louisville, Kentucky
  9. New Orleans, Louisiana
  10. Baltimore, Maryland
  11. Detroit, Michigan
  12. Kansas City, Missouri
  13. St. Louis, Missouri
  14. Bronx, New York
  15. Great Neck, New York
  16. Cincinnati, Ohio
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Columbus, Ohio
  20. Portland, Oregon
  21. Hershey, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Philadelphia, Pennsylvania
  24. Pittsburgh, Pennsylvania
  25. Memphis, Tennessee
  26. Nashville, Tennessee
  27. Houston, Texas
  28. Houston, Texas
  29. Charlottesville, Virginia
  30. Madison, Wisconsin
ALL GENDERS
6 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.
Official Title  ICMJE Peds I (Pediatric Eplerenone Development Study I): A Randomized, Double-Blind, Placebo Withdrawal, Parallel Group, Dose-Response Study To Evaluate The Efficacy And Safety Of Eplerenone In The Treatment Of Hypertension In Children
Brief Summary To evaluate the efficacy, safety, and toleration of eplerenone in the treatment of children aged 6 to 16 years with high blood pressure. The study will last approximately 10 weeks and about 320 patients will participate.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Hypertension
Intervention  ICMJE Drug: Eplerenone
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 2, 2005)
320
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 6-16 years old male and female
  • Systolic blood pressure greater than or equal to the 95th percentile for age, gender, and height, measured on at least 3 separate occasions

Exclusion Criteria:

  • K/DOQI classification of stages of chronic kidney disease equal to or greater than 3
  • Serum or whole blood potassium > 5.5 mEq/L
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 6 Years to 16 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Dominican Republic,   India,   Russian Federation,   South Africa,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00147589
Other Study ID Numbers  ICMJE A6141001
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP